Diarrhea News and Research

Latest Diarrhea News and Research

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.

22 Oct 2018

Newly discovered toxin stands out from others in the battle for microbial domination

A newly discovered toxin that some bacteria deploy to fend off competing bacteria stands out from others in the battle for microbial domination. While many deadly substances have been identified among bacteria, this previously unknown toxin behaves in a familiar way.

19 Oct 2018

Study finds differences in side-effects experienced by male and female OG cancer patients

Men and women may need to be treated differently - at least when it comes to some types of cancer. In an analysis to be presented at the ESMO 2018 Congress in Munich, data was pooled from four UK randomized controlled clinical trials of first line chemotherapy in oesophagogastric cancer, finding significant differences in a number of important side-effects experienced by male and female patients.

19 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Study findings may explain sporadic outbreaks of C. difficile infections in hospitals

Washing contaminated hospital bedsheets in a commercial washing machine with industrial detergent at high disinfecting temperatures failed to remove all traces of Clostridium difficile (C. difficile), a bacteria that causes infectious diarrhea, suggesting that linens could be a source of infection among patients and even other hospitals, according to a study published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

16 Oct 2018

Novel 3-in-1 vaccine designed against traveler’s diarrhea

A first-ever vaccine designed to deliver a one-two-three punch against the main causes of traveler's diarrhea worldwide may result from new research published by a University of Guelph chemist.

11 Oct 2018

Unrecognized childhood infections far greater threat than previously realized

Children around the world are suffering from unnoticed infections that are stunting their growth and mental development, new research from an international coalition of scientists reveals.

10 Oct 2018

Prenatal inflammation may explain why some infants are more prone to neonatal sepsis

Each year 15 million infants are born preterm and face high risks of short- and long-term complications, including sepsis, severe inflammation of the gut, and neurodevelopmental disorders.

9 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

New ReFRAME drug repurposing collection offers hope for treating major diseases

Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?

4 Oct 2018

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Genentech, a member of the Roche Group, announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam in spinal muscular atrophy.

3 Oct 2018

Researchers find human milk oligosaccharides in amniotic fluid

Human milk oligosaccharides are complex carbohydrates that are highly abundant and unique to human milk.

3 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of patients with the disease who do not respond to conventional treatment.

29 Sep 2018

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

28 Sep 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Diarrhea News and Research

Latest Diarrhea News and Research

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

Newly discovered toxin stands out from others in the battle for microbial domination

Study finds differences in side-effects experienced by male and female OG cancer patients

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Study findings may explain sporadic outbreaks of C. difficile infections in hospitals

Novel 3-in-1 vaccine designed against traveler’s diarrhea

Unrecognized childhood infections far greater threat than previously realized

Prenatal inflammation may explain why some infants are more prone to neonatal sepsis

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

New ReFRAME drug repurposing collection offers hope for treating major diseases

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Researchers find human milk oligosaccharides in amniotic fluid

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Protective gel sphere may offer probiotics a safer route to the intestines

American Cancer Society releases new cookbook for cancer patients

Researchers aim to develop vaccine for 'traveler's diarrhea'

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Diarrhea News and Research

Latest Diarrhea News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in